Infliximab as a treatment for systemic amyloidosis associated with Crohn's disease.
Iizuka
M
M
Konno
S
S
Horie
Y
Y
Itou
H
H
Shindo
K
K
Watanabe
S
S
D000328:Adult; D000686:Amyloidosis / Q000150:complications / Q000628:therapy*; D000911:Antibodies, Monoclonal / Q000627:therapeutic use*; D003424:Crohn Disease / Q000150:complications / Q000628:therapy*; D005765:Gastrointestinal Agents / Q000627:therapeutic use*; D006801:Humans; D000069285:Infliximab; D007674:Kidney Diseases / Q000209:etiology / Q000628:therapy; D008297:Male; D000685:Serum Amyloid A Protein / Q000032:analysis; D014409:Tumor Necrosis Factor-alpha / Q000037:antagonists & inhibitors*
D000911:Antibodies, Monoclonal; D005765:Gastrointestinal Agents; D000685:Serum Amyloid A Protein; D014409:Tumor Necrosis Factor-alpha; D000069285:Infliximab